PCR using allele-specific probes, and CYP2C9*3 by PCR-RFLP. PHT plasma levels were determined by radioimmunoassay. Results: Twenty-six patients showed PHT therapeutic levels (10-20 µg/mL), 24 subtherapeutic and 7 supratherapeutic. Three cases, 2 CYP2C9 *1/*2, and 1 CYP2C19*1/3, had subtherapeutic levels. Patients with wild-type ABCB1 and ABCC2 genotypes exhibited a tendency to have increased PHT plasma levels than patients with mutant genotypes. Conclusion: PHT plasma levels showed great variability among patients that was not statistically significant correlated to the genetic polymorphisms analyzed, although ABCB1 and ABCC2 wild-type genotypes showed a trend toward higher levels. Further investigations are needed with other candidate genes and a larger sample.
Aspirin is an antiplatelet agent commonly used in treatment of patients with high risk to develop stroke and myocardial infarction. However, interindividual variability regarding the inhibition of platelet function by aspirin is well documented. In this study, the correlation between platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) polymorphisms and antiplatelet response in patients treated with aspirin was investigated. Patients (or Materials) and Methods: Jordanian adult patients (n = 584) who are taking aspirin as an antiplatelet agent participated in the study. Platelet aggregation response was measured using Multiplate Analyzer® system. Polymerase chain reaction-restriction fragment length polymorphism assay (PCR-RFLP) was used for genotyping of the examined polymorphisms. Results: Aspirin resistance was found in 15.8% of patients. Response to aspirin was significantly associated with GPIba C-5T polymorphism (P < 0.05). However, the GPIa C807T and COX-2 G-765C polymorphisms were not related to aspirin resistance (P > 0.05). Conclusion: A considerable fraction of the Jordanian population is resistant to the antiplatelet effect of aspirin, which might be related to GPIba C-5T polymorphism. Disclosure of Interest: None declared. 3 Clinical Pathology, Medical Research Institute, University of Alexandria, Alexandria, Egypt Introduction: Pharmacogenomics is intervening in cardiovascular therapeutic armamentarium to tailor therapy to individual's genetic makeup. Accordingly, the potential implication of PlA gene variants of GPIIIa of platelet GP IIb/IIIa as a genetic risk factor provocateur and/or a therapeutic outcome modulator to antiplatelet therapy in ACS was probed. Patients (or Materials) and Methods: Study enrolled 22 controls and 44 ACS patients (NSTEMI vs STEMI). They were risk stratified (TIMI score), sampled for genotyping and estimation of platelet aggregation and oxidative indices, then subdivided according to add-on antiplatelet therapy into: clopidogrel or tirofiban subgroups. After 48 hours, the therapeutic outcome was assessed; clinically [pain relief or complication prevalence (symptomatic, electrocardiographic, or hemorrhagic) and the investigational estimates were re-assessed. Intraprocedural evaluation of chest pain, ECG tracing, and angiographic findings (thrombus extent, TIMI flow, myocardial blush) were reported in patients who underwent percutaneous intervention [PCI] . Results: Frequency of PlA2 vs PlA1 allele was higher in ACS patients (significant in < 60 years /doubled in STEMI vs NSTEMI). TIMI score, stratification permitted considering PlA2 variant as independent risk factor in UA/NSTEMI subsets. This was fostered by intraprocedural finding of more stenotic and thrombotic lesions in PlA2 carriers. A lack of significant association between PlA variants and changes in platelet aggregation or oxidative indices, debate their causal relation to PlA2 variant being an ACS risk factor. A positive correlation was observed between PlA variants and the therapeutic response outcome to both clopidogrel and tirofiban regarding platelet aggregation and relief of chest pain while their antioxidative potentiality was negatively correlated only to PlA1 carriers. Conclusion: PlA2 variant could be considered a genetic risk factor contributor rather than an antiplatelet therapeutic response modulator when speaking of ACS. This awaits larger scale pharmacogenomic studies before a final statement is declared so as to individualize antiplatelet therapy to the best of its therapeutic outcome in ACS settings. Disclosure of Interest: None declared. Ultrarapid drug metabolism (UM) mediated by CYP2D6 is associated with duplicated or amplified functional CYP2D6 alleles. However, duplicated CYP2D6 alleles only explains a fraction (10%-30%) of the UM phenotype observed in Caucasian populations, and other biochemical and/or genetic factors involved in UM phenotype remain unexplained yet. CYP2D6 -1584C> G has been related with changes in CYP2D6 expression, being -1584G associated with higher expression. The aim of this study was to explore the relationship between CYP2D6 -1584C> G polymorphism and the debrisoquine hydroxylation capacity.
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